Skip to main content

Table 2 Prescribed medication at baseline and at 6-months follow-up for those who remained in the trial (n = 146)

From: The effect of a comprehensive lifestyle intervention on cardiovascular risk factors in pharmacologically treated patients with stable cardiovascular disease compared to usual care: a randomised controlled trial

Drug class Baseline data for those who remained in the trial Data at 6-months follow-up  
Intervention n = 59 Control n = 60 Intervention n = 59 Control n = 60
Antithrombotica   
Acetylsalicylic acid (aspirin) 47 (79.7%) 54 (90.0%) 49 (83.1%) 52 (86.7%)
Blood pressure-lowering medication    
Angiotensin-converting enzyme (ACE inhibitors) 24 (40.7%) 21 (35.0%) 27 (45.8%) 20 (33.3%)
β-blocker 34 (57.6%) 38 (63.3%) 33 (55.9%) 40 (66.7%)
Calcium-channel blocker 12 (20.3%) 19 (31.7%) 16 (27.1%) 18 (30.0%)
Diuretica 12 (20.3%) 12 (20.0%) 12 (20.3%) 10 (16.7%)
Lipid-lowering medication     
Statins 51 (86.4%) 49 (81.7%) 53 (89.8%) 54 (90.0%)
Blood glucose-lowering medication a     
Biguanides 9 (15.3%) 7 (11.7%) 10 (16.9%) 7 (11.7%)
  1. n=number of patients; %, percentage of patients who remained in the study; adata based on diabetic patients at baseline and at 6-months follow-up.